Publication | Closed Access

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

Adverse EventsGrade 3/4OncologyCancer ManagementOutcomes ResearchBronchial NeoplasmPharmacotherapyCancer TreatmentPemetrexed Maintenance TherapyMedicineRadiation OncologyLung Cancer